Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Oxidative modification of serum proteins in multiple sclerosis.
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Treatment of neuromyelitis optica.
Imaging outcomes for trials of remyelination in multiple sclerosis.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Architecture of human mTOR complex 1.
First proof for rituximab in IgG4-related disease
Fourth PML Case With Tecfidera in MS Calls for Vigilance
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Application of fullerenes in nanomedicine: an update.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
Optimizing IFN Beta - 1B Dose (Optims)
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.

Pages